AUSTIN,
Texas, April 25, 2022 /PRNewswire/ -- VolitionRx
Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national
epigenetics company developing simple, easy to use, cost effective
blood tests to help diagnose and monitor a range of cancers and
other life-altering diseases in both humans and animals, has
announced the launch of its
Nu.Q® Vet Cancer Test in Asia through its appointed distributor
SAGE Healthcare Private Limited.
As previously announced, SAGE was appointed in December 2021 to serve as a non-exclusive
licensee and distributor for Volition's Nu.Q® Vet
Cancer Test in centralized labs in Singapore. Following pre-launch preparations,
SAGE hosted a launch event featuring Professor Heather Wilson-Robles, Chief Medical Officer,
Volition Veterinary, and Dr. Tom
Butera, Chief Executive Officer, Volition Veterinary on
Friday, April 22. SAGE is now
actively marketing the Test and will be processing samples and
providing test results from its centralized lab with immediate
effect.
Dr. Jasmine Kway, Chief Executive
Officer of Singapore Volition, commented "With rapid urbanization
and rising disposable income, pets have become an important part of
Asian families. Over half of the Asian population have a companion
animal, with almost a third of households owning a dog. We believe
that the opportunity for the Nu.Q® Vet Cancer Test
is huge. SAGE Healthcare is one of the strongest and most respected
distributors of leading veterinary brands in Singapore and we are delighted that the launch
event was so well attended, and that active sales and marketing
efforts are now underway."
"Adding the Nu.Q® Vet Cancer Test to the routine
wellness check-up for older dogs and at-risk breeds could help
detect cancer early, when treatment is more effective and
affordable. We believe that this is a clear unmet need in the
veterinary space," commented Ms. Irene
Kum, General Manager for SAGE Healthcare Private Limited.
"We are excited to launch the test in Singapore and hope to develop subsequent
launch plans in other Asian markets in the future."
Volition is developing simple, easy-to-use, cost-effective blood
tests to help diagnose and monitor a range of life-altering
diseases including cancer in both humans and animals. For more
information about Volition's Nu.Q® technology go to:
www.volition.com
About Volition
Volition is a multi-national epigenetics company that applies
its Nucleosomics™ platform through its subsidiaries to develop
simple, easy to use, cost effective blood tests to help diagnose
and monitor a range of life-altering diseases including some
cancers and diseases associated with NETosis such as sepsis and
COVID-19. Early diagnosis and monitoring have the potential to not
only prolong the life of patients but also improve their quality of
life. The tests are based on the science of Nucleosomics™, which is
the practice of identifying and measuring nucleosomes in the
bloodstream or other bodily fluid, which can indicate that disease
is present. Volition is primarily focused on human diagnostics and
monitoring but also has a subsidiary focused on animal diagnostics
and monitoring.
Volition's research and development activities are centered in
Belgium, with an innovation
laboratory in California and
additional offices in Texas,
London, and Singapore, as the company focuses on bringing
its diagnostic and disease monitoring products to market.
For more information about Volition, visit Volition's website or
connect with us via Twitter, LinkedIn, and Facebook. The
contents found at Volition's website, Twitter, LinkedIn and
Facebook are not incorporated by reference into this document and
should not be considered part of this document.
Media Enquiries:
Louise Batchelor/Debra Daglish, Volition,
mediarelations@volition.com +44 (0)7557 774620
Investor Enquiries:
Scott Powell, Volition,
investorrelations@volition.com +1 (646) 650 1351
Joseph Green, Edison Advisors,
jgreen@edisongroup.com +1 (646) 653 7030
Safe Harbor Statement
Statements in this press release may be "forward-looking
statements" within the meaning of Section 27A of the Securities Act
of 1933, as amended, and Section 21E of the Securities Exchange Act
of 1934, as amended, that concern matters that involve risks and
uncertainties that could cause actual results to differ materially
from those anticipated or projected in the forward-looking
statements. Words such as "expects," "anticipates," "intends,"
"plans," "aims," "targets," "believes," "seeks," "estimates,"
"optimizing," "potential," "goal," "suggests," "can," "could,"
"would," "should," "may," "will" and similar expressions identify
forward-looking statements. These forward-looking statements relate
to Volition's expected market opportunity for its Nu.Q®
Vet Cancer Test, the effectiveness of Volition's blood-based
diagnostic, prognostic and disease monitoring tests, Volition's
ability to develop and successfully commercialize such test
platforms for early detection of cancer and other diseases as well
as serving as a diagnostic, prognostic or disease monitoring tools
for such diseases, and the timing and execution of product launches
and publications. Volition's actual results may differ materially
from those indicated in these forward-looking statements due to
numerous risks and uncertainties, including, without limitation,
results of studies testing the efficacy of its tests. For instance,
if Volition fails to develop and commercialize diagnostic,
prognostic or disease monitoring products, it may be unable to
execute its plan of operations. Other risks and uncertainties
include Volition's failure to obtain necessary regulatory
clearances or approvals to distribute and market future products; a
failure by the marketplace to accept the products in Volition's
development pipeline or any other diagnostic, prognostic or disease
monitoring products Volition might develop; Volition's failure to
secure adequate intellectual property protection; Volition will
face fierce competition and Volition's intended products may become
obsolete due to the highly competitive nature of the diagnostics
and disease monitoring markets and their rapid technological
change; downturns in domestic and foreign economies; and other
risks identified in Volition's most recent Annual Report on Form
10-K and Quarterly Reports on Form 10-Q, as well as other documents
that Volition files with the Securities and Exchange Commission.
These statements are based on current expectations, estimates and
projections about Volition's business based, in part, on
assumptions made by management. These statements are not guarantees
of future performance and involve risks, uncertainties and
assumptions that are difficult to predict. Forward-looking
statements are made as of the date of this release, and, except as
required by law, Volition does not undertake an obligation to
update its forward-looking statements to reflect future events or
circumstances.
Nucleosomics™ and Nu.Q® and their respective logos
are trademarks and/or service marks of VolitionRx Limited and its
subsidiaries. All other trademarks, service marks and trade names
referred to in this press release are the property of their
respective owners.
View original
content:https://www.prnewswire.com/news-releases/volition-launches-its-nuq-vet-cancer-test-in-asia-through-its-appointed-distributor-sage-healthcare-301531770.html
SOURCE VolitionRx Limited